Mark Ratner. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Administration, OralAnimalsClinical Trials as TopicDrug Approval/economicsDrug Industry/economicsFingolimod HydrochlorideHumansLymphocytes/metabolismLysophospholipids/metabolismMultiple Sclerosis/drug therapyMultiple Sclerosis/economicsPropylene Glycols/administration & dosagePropylene Glycols/adverse effectsPropylene Glycols/economicsPropylene Glycols/therapeutic useSphingosine/administration & dosageSphingosine/adverse effectsSphingosine/analogs & derivativesSphingosine/economicsSphingosine/metabolismSphingosine/therapeutic use
Substances： See more » LysophospholipidsPropylene Glycolssphingosine 1-phosphateFingolimod HydrochlorideSphingosine
Year: 2010 PMID： 21057464 DOI： 10.1038/nbt1110-1135
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908